BRPI0920259A2 - molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea - Google Patents

molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea

Info

Publication number: BRPI0920259A2
Authority: BR; Brazil
Prior art keywords: factor molecule; blood factor; modified; modified blood; treating
Prior art date: 2008-10-17

Application number

BRPI0920259A

Other languages

English (en)

Inventor

Hanspeter Rottensteiner

Juergen Siekmann

Peter Turecek

Original Assignee

Baxter Int

Baxter Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-17

Filing date

2009-10-16

Publication date

2016-01-05

2009-10-16 Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int

2016-01-05 Publication of BRPI0920259A2 publication Critical patent/BRPI0920259A2/pt

2017-09-19 Publication of BRPI0920259A8 publication Critical patent/BRPI0920259A8/pt

Links

229960000182 blood factors Drugs 0.000 title 2
206010053567 Coagulopathies Diseases 0.000 title 1
230000023555 blood coagulation Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

BRPI0920259A 2008-10-17 2009-10-16 Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea BRPI0920259A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10642408P	2008-10-17	2008-10-17
PCT/US2009/061023 WO2010045568A1 (en)	2008-10-17	2009-10-16	Modified blood factors comprising a low degree of water soluble polymer

Publications (2)

Publication Number	Publication Date
BRPI0920259A2 true BRPI0920259A2 (pt)	2016-01-05
BRPI0920259A8 BRPI0920259A8 (pt)	2017-09-19

Family

ID=41650072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920259A BRPI0920259A8 (pt)	2008-10-17	2009-10-16	Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea

Country Status (20)

Country	Link
US (4)	US20100099616A1 (pt)
EP (3)	EP3437661A1 (pt)
JP (2)	JP5785872B2 (pt)
KR (2)	KR20110071012A (pt)
AU (1)	AU2009305612B2 (pt)
BR (1)	BRPI0920259A8 (pt)
CA (1)	CA2738679A1 (pt)
CY (1)	CY1120921T1 (pt)
DK (1)	DK2349342T3 (pt)
ES (1)	ES2692172T3 (pt)
HR (1)	HRP20181454T1 (pt)
HU (1)	HUE039906T2 (pt)
LT (1)	LT2349342T (pt)
MX (1)	MX2011004085A (pt)
NZ (1)	NZ592688A (pt)
PL (1)	PL2349342T3 (pt)
PT (1)	PT2349342T (pt)
SI (1)	SI2349342T1 (pt)
SM (1)	SMT201800486T1 (pt)
WO (1)	WO2010045568A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10201401194VA (en) *	2009-07-27	2014-07-30	Lipoxen Technologies Ltd	Glycopolysialylation of non-blood coagulation proteins
EP2536753B1 (en)	2010-02-16	2017-12-20	Novo Nordisk A/S	Factor viii molecules with reduced vwf binding
GB201007356D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
WO2012007324A2 (en) *	2010-07-15	2012-01-19	Novo Nordisk A/S	Stabilized factor viii variants
JP6352806B2 (ja)	2011-09-23	2018-07-04	ノヴォノルディスクアー／エス	新規のグルカゴン類似体
GB2516388A (en) *	2012-04-16	2015-01-21	Cantab Biopharmaceuticals Patents Ltd	Optimised subcutaneous therapeutic agents
CA2909581A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
EP3177317B1 (en)	2014-08-04	2020-03-18	CSL Limited	Factor viii formulation
KR20170125941A (ko)	2015-03-06	2017-11-15	체에스엘 베링 리컴비넌트 퍼실리티 아게	개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
JP6552286B2 (ja) *	2015-06-05	2019-07-31	公立大学法人奈良県立医科大学	凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
JP7780341B2 (ja)	2019-07-04	2025-12-04	ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト	第ＶＩＩＩ凝固因子のｉｎｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ）
US20220348637A1 (en)	2019-11-11	2022-11-03	CSL Behring Lengnau AG	Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4757006A (en) *	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
US6048729A (en) *	1987-05-01	2000-04-11	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) *	1991-11-05	2000-05-16	Transkaryotic Therapies, Inc.	Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en)	1992-04-10	2000-03-14	Alpha Therapeutic Corporation	Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) *	1992-12-22	1994-03-29	Enzon, Inc.	Aryl imidate activated polyalkylene oxides
AU6029594A (en)	1993-01-15	1994-08-15	Enzon, Inc.	Factor viii - polymeric conjugates
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US6238908B1 (en) *	1995-06-07	2001-05-29	Aastrom Biosciences, Inc.	Apparatus and method for maintaining and growth biological cells
US7074878B1 (en)	1999-12-10	2006-07-11	Harris J Milton	Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) *	2001-06-26	2003-11-13	Nelsestuen Gary L.	High molecular weight derivatives of vitamin k-dependent polypeptides
WO2004000366A1 (en) *	2002-06-21	2003-12-31	Novo Nordisk Health Care Ag	Pegylated factor vii glycoforms
CA2507904C (en)	2002-12-19	2014-12-02	M. Elizabeth Snell	Cyanovirin variant-polymer conjugates
LT1596887T (lt) *	2003-02-26	2022-04-25	Nektar Therapeutics	Polimero-faktoriaus viii fragmento konjugatai
AU2004221824B2 (en) *	2003-03-14	2009-08-27	Ratiopharm Gmbh	Branched water-soluble polymers and their conjugates
KR101100059B1 (ko) *	2004-06-30	2011-12-29	넥타르 테라퓨틱스	중합체인자 ｉｘ 부분의 접합체
MX350293B (es) *	2004-11-12	2017-09-04	Bayer Healthcare Llc	Modificacion dirigida al sitio del factor viii.
DK1835938T3 (da) *	2004-12-27	2013-11-04	Baxter Int	Polymer-von Willebrand-faktor-konjugater
EP1893230A2 (en) *	2005-04-26	2008-03-05	Maxygen Holdings Ltd.	Use of modified factor vii for treating bleeding
EP1891231A4 (en) *	2005-05-25	2011-06-22	Novo Nordisk As	GLYCOPEGYLATED FACTOR IX
US7645860B2 (en) *	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
NZ572050A (en)	2006-03-31	2011-09-30	Baxter Int	Factor VIII conjugated to polyethylene glycol
CN103804489A (zh) *	2006-12-15	2014-05-21	巴克斯特国际公司	具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
US8133865B2 (en)	2006-12-27	2012-03-13	Nektar Therapeutics	von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage

2009
- 2009-10-16 JP JP2011532289A patent/JP5785872B2/ja active Active
- 2009-10-16 WO PCT/US2009/061023 patent/WO2010045568A1/en not_active Ceased
- 2009-10-16 PL PL09752930T patent/PL2349342T3/pl unknown
- 2009-10-16 EP EP18179965.1A patent/EP3437661A1/en not_active Withdrawn
- 2009-10-16 KR KR1020117011049A patent/KR20110071012A/ko not_active Ceased
- 2009-10-16 AU AU2009305612A patent/AU2009305612B2/en active Active
- 2009-10-16 EP EP09752930.9A patent/EP2349342B1/en active Active
- 2009-10-16 HR HRP20181454TT patent/HRP20181454T1/hr unknown
- 2009-10-16 DK DK09752930.9T patent/DK2349342T3/en active
- 2009-10-16 LT LTEP09752930.9T patent/LT2349342T/lt unknown
- 2009-10-16 ES ES09752930.9T patent/ES2692172T3/es active Active
- 2009-10-16 CA CA2738679A patent/CA2738679A1/en not_active Abandoned
- 2009-10-16 US US12/580,786 patent/US20100099616A1/en not_active Abandoned
- 2009-10-16 KR KR1020167022913A patent/KR101929641B1/ko active Active
- 2009-10-16 NZ NZ592688A patent/NZ592688A/xx unknown
- 2009-10-16 MX MX2011004085A patent/MX2011004085A/es active IP Right Grant
- 2009-10-16 PT PT09752930T patent/PT2349342T/pt unknown
- 2009-10-16 BR BRPI0920259A patent/BRPI0920259A8/pt not_active Application Discontinuation
- 2009-10-16 SI SI200931874T patent/SI2349342T1/sl unknown
- 2009-10-16 EP EP19189998.8A patent/EP3620177A1/en not_active Withdrawn
- 2009-10-16 SM SM20180486T patent/SMT201800486T1/it unknown
- 2009-10-16 HU HUE09752930A patent/HUE039906T2/hu unknown
2011
- 2011-09-23 US US13/242,934 patent/US20120076749A1/en not_active Abandoned
2015
- 2015-03-20 JP JP2015057790A patent/JP2015110676A/ja active Pending
2016
- 2016-01-08 US US14/991,172 patent/US20160199503A1/en not_active Abandoned
2018
- 2018-09-24 CY CY181100982T patent/CY1120921T1/el unknown
- 2018-10-30 US US16/175,744 patent/US20190160178A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2349342T3 (en)	2018-10-08
US20120076749A1 (en)	2012-03-29
AU2009305612B2 (en)	2015-05-21
BRPI0920259A8 (pt)	2017-09-19
EP3620177A1 (en)	2020-03-11
JP2015110676A (ja)	2015-06-18
EP3437661A1 (en)	2019-02-06
WO2010045568A1 (en)	2010-04-22
US20100099616A1 (en)	2010-04-22
SI2349342T1 (sl)	2018-10-30
US20160199503A1 (en)	2016-07-14
PT2349342T (pt)	2018-10-26
ES2692172T3 (es)	2018-11-30
HUE039906T2 (hu)	2019-02-28
KR20160103173A (ko)	2016-08-31
KR20110071012A (ko)	2011-06-27
LT2349342T (lt)	2018-10-10
EP2349342B1 (en)	2018-06-27
CA2738679A1 (en)	2010-04-22
HRP20181454T1 (hr)	2018-12-14
SMT201800486T1 (it)	2018-11-09
JP5785872B2 (ja)	2015-09-30
PL2349342T3 (pl)	2019-01-31
NZ592688A (en)	2012-12-21
MX2011004085A (es)	2011-09-27
CY1120921T1 (el)	2019-12-11
EP2349342A1 (en)	2011-08-03
US20190160178A1 (en)	2019-05-30
AU2009305612A1 (en)	2010-04-22
JP2012505917A (ja)	2012-03-08
KR101929641B1 (ko)	2018-12-14

Legal Events

Date	Code	Title	Description
2017-09-19	B25A	Requested transfer of rights approved	Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B15K	Others concerning applications: alteration of classification	Ipc: A61K 47/61 (2017.01), A61K 38/37 (2006.01), A61K 3
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-03	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-03-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-06-22	B07B	Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2618 DE 09/03/2021 POR TER SIDO INDEVIDA.
2021-07-13	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-08-17	B25A	Requested transfer of rights approved	Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)
2021-11-23	B09B	Patent application refused [chapter 9.2 patent gazette]
2022-02-08	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI0920259A2 (pt)	2016-01-05	molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI1008145A2 (pt)	2016-03-15	proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BRPI1005153A2 (pt)	2019-09-24	composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BR112013026341A2 (pt)	2019-09-24	composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0909691A2 (pt)	2015-08-04	Composto, método para preparar um composto, e, composição farmacêutica
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BR112013031712A2 (pt)	2017-07-04	composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
CY2016053I1 (el)	2017-06-28	Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0922566A2 (pt)	2017-03-28	polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0906466A2 (pt)	2015-07-14	Composição para cuidado oral, e, métodos para preparar uma composição oral, e para aplicar uma quantidade eficaz da composição oral
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
EP2701700A4 (en)	2015-10-21	PHARMACOTHERAPY FOR PREVENTING ADVERSE EFFECTS INDUCED BY CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING METHODS AND KITS THEREOF
BRPI0909198A2 (pt)	2019-09-24	composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
EP2318026A4 (en)	2012-09-12	COMPOSITION FOR CONTROLLING AN INCREASE IN GLYCEMIA
BRPI0923856A2 (pt)	2015-10-20	composto, composição farmacêutica, uso de um composto, e método para tratar uma doença ou distúrbio.
BRPI0814300A2 (pt)	2015-02-03	Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI0920933A2 (pt)	2019-09-24	molécula de ácido nucleico de dupla fita, composição farmacêutica, e, método para tratar um indivíduo humano sofrendo de uma condição